Malin Corporation plc

Malin Corporation plc is a publicly listed company headquartered in Dublin, Ireland, focusing on investing in and supporting highly innovative life sciences companies. The company aims to deliver significant returns for shareholders and transformative outcomes for patients by applying long-term capital and strategic support to its investee companies, enabling them to reach their value potential. Malin is listed on the Euronext Growth Market of Euronext Dublin.

The company's investment strategy centers on sectors such as oncology, immunology, and genetic diseases, where it believes innovative life science and healthcare technologies can deliver transformative treatments for patients. Malin's portfolio includes investments in private, pre-IPO, and pre-trade sale operating businesses in the life sciences industry, with post-investment valuations ranging from $10 million to $250 million.

Over the years, Malin has returned significant capital to shareholders through the sale of its interests in various companies, including Immunocore, Kymab, and Altan Pharmaceuticals. In February 2025, Malin announced plans to repurchase up to 76% of its remaining shares, utilizing cash raised from the sale of its stakes in biopharmaceutical companies. This move is part of the company's strategy to wind down operations and return value to shareholders.

Malin's portfolio companies have achieved notable milestones, such as Poseida Therapeutics, which was acquired by Roche in a deal valued at up to $1.5 billion, resulting in a substantial return for Malin's shareholders. The company's focus on strategic investments in the life sciences sector has positioned it as a significant player in the field, with a commitment to advancing healthcare through innovative solutions.

Malin Corporation plc continues to manage its remaining investments, aiming to maximize value for shareholders while supporting the growth and development of its portfolio companies in the life sciences industry.